Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph phase_4
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 41 (100.0%)

Trials by Status

unknown150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingphase_4

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

NCT06818474
unknown

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

NCT04583007

Clinical Trials (2)

Showing 2 of 2 trials
NCT06818474Phase 4

Lanadelumab in Long-term Prophylaxis of Acquired Angioedema

Recruiting
NCT04583007

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Unknown

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2